VIRACTA THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
VIRACTA THERAPEUTICS INC. - More news...
VIRACTA THERAPEUTICS INC. - More news...
- Viracta Therapeutics Announces Wind Down of Operations
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
- Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma
- Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan
- Viracta Therapeutics Announces New Employment Inducement Grants
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
- Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
- Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
- Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
- Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial
- Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Viracta Therapeutics Provides Clinical Update and Outlook for 2024
- Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma
- Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels
- Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
- Viracta Therapeutics to Present at Upcoming Investor Conferences
- Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
- Viracta Therapeutics to Host R&D Day on October 4, 2023
- Viracta Therapeutics Announces New Employment Inducement Grant
- Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma
- Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
- Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)
- Viracta Therapeutics to Present at the Jefferies Healthcare Conference
- Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
